CDP323 is an antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis... It is considered a small-molecule prodrug.
- Mechanism
- Curator reviewed
CDP323 is believed to stop immune cells from migrating from blood vessels walls to reach other tissues, including tissues in the central nervous system, where they can cause encephalomyelitis (or inflammation of the white matter in the brain and spinal cord). This inhibition of cell migration prevents immunogenic reactions that lead to tissue damage, which is often a consequence of uncontrolled cell migration.
- Primary indication
- Investigated for use/treatment in multiple sclerosis.Curator reviewed
- Also known as
- Zaurategrast ethyl ester
- Code names
- CDP323 · UCB-1184197
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with UCB-1184197, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account